Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069072 | 1.00 | ABCG2 (0.47) | ABCG2BRD4SMN1; SMN2EGFRHCRTR1 | |
| SCHEMBL28687296 | 0.95 | ABCG2 (0.43) | ABCG2BRD4SMN1; SMN2EGFRHCRTR1 | |
| SCHEMBL1065239 | 0.84 | MAPT (0.39) | ABCG2SMN1; SMN2CYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL21275234 | 0.81 | SMN1; SMN2 (0.48) | BRD4SMN1; SMN2EGFRALDH1A1LMNA | |
| SCHEMBL30567482 | 0.81 | SMN1; SMN2 (0.48) | BRD4SMN1; SMN2EGFRALDH1A1LMNA | |
| SCHEMBL12672000 | 0.79 | MAP2K1 (0.33) | BRD4EGFR | |
| SCHEMBL1066484 | 0.77 | MAPT (0.34) | SMN1; SMN2EGFRCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL23164344 | 0.75 | MAPT (0.36) | SMN1; SMN2CYP2C19ALDH1A1LMNAMEN1 | |
| SCHEMBL23164382 | 0.75 | SRC (0.33) | BRD4SMN1; SMN2EGFRCYP2C19ALDH1A1 | |
| SCHEMBL23165052 | 0.75 | MAPT (0.41) | SMN1; SMN2EGFRLMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390368-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. | 2024-11-28 | — | — | US | disclosed |
| CN-116406259-A | Dosage form compositions comprising inhibitors of BTK and mutants thereof | 广州麓鹏制药有限公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-4196124-A1 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023076167-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022036171-A1 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390368-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | BTK, LYN, JAK2 | ABCG2 2801/4885BRD4 691/4885SMN1; SMN2 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.